{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:13:20Z","timestamp":1784132000947,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.urology.2015.12.049","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T17:47:31Z","timestamp":1452275251000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Use of Botulinum Toxin in Urologic Diseases"],"prefix":"10.1016","volume":"91","author":[{"given":"Christopher J.","family":"Chermansky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2015.12.049_bib0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/mus.10213","article-title":"Comparison of neuromuscular blockade and recovery with botulinum toxins A and F","volume":"26","author":"Billante","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.urology.2015.12.049_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ncpuro1124","article-title":"Drug insight: biological effects of botulinum toxin A in the lower urinary tract","volume":"5","author":"Chancellor","year":"2008","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2015.12.049_bib0035","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0040","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0045","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 u significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","article-title":"A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200\u2009U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"192","author":"McVary","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.12.049_bib0065","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrn2401","article-title":"The neural control of micturition","volume":"9","author":"Fowler","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.urology.2015.12.049_bib0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","article-title":"Pharmacotherapy for neurogenic detrusor overactivity","volume":"85","author":"Chancellor","year":"2006","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.urology.2015.12.049_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urology.2004.08.016","article-title":"Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra","volume":"65","author":"Smith","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.12.049_bib0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0090","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2015.12.049_bib0100","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.urology.2015.12.049_bib0105","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0b013e3182a2ca4d","article-title":"OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity","volume":"81","author":"Chancellor","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.urology.2015.12.049_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/nau.22934","article-title":"Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study","author":"Kennelly","year":"2015","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.urology.2015.12.049_bib0110","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and disport (abotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0115","doi-asserted-by":"crossref","DOI":"10.1111\/iju.12950","article-title":"Failure of botulinum toxin injection for neurogenic detrusor overactivity: switch of toxin versus second injection of the same toxin","author":"Peyronnet","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.urology.2015.12.049_bib0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0130","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0140","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0145","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2015.12.049_bib0150","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.urology.2015.12.049_bib0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00192-014-2499-2","article-title":"Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events","volume":"26","author":"Davis","year":"2015","journal-title":"Int Urogynecol J"},{"issue":"4 suppl","key":"10.1016\/j.urology.2015.12.049_bib0165","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1016\/j.juro.2015.02.2932","article-title":"Durable reductions in urinary incontinence with long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of 3.5-year study","volume":"193","author":"Nitti","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0170","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","article-title":"Placebo controlled, randomized, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients","volume":"76","author":"Gallien","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.urology.2015.12.049_bib0175","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.AOG.0000237100.29870.cc","article-title":"Botulinum toxin type A for chronic pain and pelvic floor spasm in women","volume":"108","author":"Abbott","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2015.12.049_bib0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0302-2838(02)00209-9","article-title":"Botulinum A toxin and detrusor-sphincter-dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease","volume":"42","author":"de Seze","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","article-title":"Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia; results of a randomized, placebo-controlled study","volume":"62","author":"Maria","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.12.049_bib0190","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/SPV.0b013e3182989fd8","article-title":"Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain","volume":"19","author":"Adelowo","year":"2013","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2015.12.049_bib0195","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated OnabotulinumtoxinA for patients with overactive bladder: a single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.12.049_bib0200","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429516000121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429516000121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T19:17:57Z","timestamp":1600024677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429516000121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":39,"alternative-id":["S0090429516000121"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2015.12.049","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Botulinum Toxin in Urologic Diseases","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2015.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}